Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "Company"),...
INTERSCRIPTS, INC. InterScripts Expands Strategic Nearshore Partnership with Akron Children’s, Extending Support into AI, Cybersecurity, and Clinical Informatics